#Amyloidosis researcher interested in pan-amyloid imaging and immunotherapy; early detection enthusiast; patient support group facilitator
Joined May 2017
- Tweets103
- Following101
- Followers186
- Likes654
Emily Martin retweeted
@Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus. Read the press release: attralus.com/press-releases/…. #amyloidosis
Emily Martin retweeted
Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: attralus.com/press-releases/…
Emily Martin retweeted
Fantastic work by Jon Wall, @EM4research et al
SPECT & PET tracers have different pros/cons
But this is a definite advancement in the field. Meanwhile, we are starting our REVEAL pIII trial of evuzamitide PET @DorbalaSharmila
#CardioTwitter #CVNuc #ASNC2024
Featured Science in #CardiacAmyloidosis #ASNC2024
🚨Early Evaluation 99mTc-Labeled Peptide p5+14 for the Detection of Cardiac #Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging #CVNuc By Jonathan S. Wall from Tennessee Graduate School of Medicine.
Emily Martin retweeted
Great news and look forward to the studies of this potentially paradigm changing tracer in amyloid diagnosis and management
Emily Martin retweeted
Excellent news. I-124 evuzamitide is one of the major and important developments in the systemic amyloidosis space
Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
Emily Martin retweeted
In case you missed it - a phase III trial of I-124 evuzamitide for the diagnosis of cardiac amyloidosis will kick off in early 2025
#CVNuc #CardioTwitter
Emily Martin retweeted
Encouraged that the @US_FDA has recognized the tremendous need and the role that diagnostics can play in improving outcomes for #amyloidosis patients.
⚕️🚨 Physicians: Recruitment of patients w/suspected cardiac amyloidosis in the planned Phase 3 study of AT-01 will be critical!
Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
Emily Martin retweeted
Congratulations Spencer and Attralus Team! Noninvasive molecular diagnosis of cardiac amyloidosis is crucial for early diagnosis and effective therapy. Excited to serve as PI of the Phase 3 study REVEAL-Research with EVuzamitide to Elucidate cardiac AmyLoidosis.
Emily Martin retweeted
Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
Emily Martin retweeted
Iodine (124I) evuzamitide is a #ThinkPET #radiotracer for #amyloidosis imaging with high sensitivity. In this #JACCIMG Phase I/II study, there was potential for early, presymptomatic disease detection throughout the body. bit.ly/3FQ9Mzf
#cvPET #cvImaging @EM4Research
Emily Martin retweeted
Have you heard of iodine (124I) evuzamitide (124I-P5+14)? Two papers show that this might be the next big thing for the imaging of cardiac amyloidosis.
Emily Martin retweeted
Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide in systemic #amyloidosis sciencedirect.com/science/ar…
Emily Martin retweeted
Packed house for the @AmyloidosisSupp ATTR meeting in Chicago.
Congrats on another great meeting @MurielFinkel !
Emily Martin retweeted
New Research: Development and characterization of a prototypic pan-amyloid clearing agent – a novel murine peptide-immunoglobulin fusion: Introduction
Systemic amyloidosis is a progressive disorder characterized by the extracellular… #immunology frontiersin.org/articles/10.…
Emily Martin retweeted
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023
Read more - attralus.com/press-releases/… #amyloidosis
Emily Martin retweeted
Check out this exciting new investigation into the performance of AT-01 (124I-evuzamitide) PET/CT and a comparison to 18F florbetapir by @DorbalaSharmila @sarahcud et al.
jacc.org/doi/10.1016/j.jcmg.…
#CardioTwitter #CVNuc
Emily Martin retweeted
Fantastic talk by @DorbalaSharmila on #ThinkPET for Amyloid
🔹 Molecular tracers - direct🚦of amyloid fibril
🔹New tracer 124I-Evuzamitide in clinical trials
🔹Can quantify WB amyloid load
🔹Quantitative PET - possible role in amyloid depleting Rx
@NotNoninvasive @MyASNC #CVNuc
Emily Martin retweeted
Future of cardiac amyloidosis diagnostics: #evuzamitide. Heart Failure Grand Rounds @HarringtonHVI @UHhospitals Dr. Justin Grodin @JLGRodin
Emily Martin retweeted
This is an interesting case published by @MathewMaurer et al in @JNCjournal
64 yo AA man, HCM hx, found + V122I. PYP -ve, CMR no LGE. AL w/u -ve. EMBx confirmed ATTR-CM. Underwent AT-01 (I-124 evuzamitide) PET/CT which was positive.
#CardioTwitter #CVNuc #Echofirst #WhyCMR
Emily Martin retweeted
Attralus receives FDA and EMA orphan designation for AT-01 as a #diagnostic for the management of ATTR and AL #amyloidosis. Read more @ ow.ly/QrZ850M6Vsg.
